Related Experiment Videos
Recombinant tissue plasminogen activator following paediatric cataract surgery
1Strabismus and Paediatric Service, Moorfields Eye Hospital, London. jodmehta@hotmail.com
The British Journal of Ophthalmology
|September 1, 2000
Summary
Recombinant tissue plasminogen activator (r-TPA) effectively treated severe fibrinous membranes after pediatric cataract surgery. This treatment was safe, aiding visual recovery and reducing steroid use in children.
Area of Science:
- Ophthalmology
- Pediatric Surgery
Background:
- Recombinant tissue plasminogen activator (r-TPA) is used for postsurgical fibrinous membranes in adults.
- Its efficacy and safety in pediatric cases are not well-documented.
Purpose of the Study:
- To evaluate the safety and effectiveness of r-TPA in treating pediatric patients with postsurgical fibrinous membranes after cataract extraction.
Main Methods:
- Retrospective review of pediatric cataract extractions at Moorfields Eye Hospital (1997-1999).
- Analysis of four patients who received intracameral injection of 25 microg r-TPA.
Main Results:
- Complete resolution of fibrinous membranes occurred in all four treated pediatric patients.
- No complications were observed at the 3-month follow-up.
- Treated patients were female and of Afro-Caribbean origin; injection occurred 4-14 days post-surgery.
Conclusions:
- A 25 microg dose of r-TPA appears safe and effective for severe fibrinous membranes post-pediatric cataract surgery.
- r-TPA facilitated visual recovery and allowed for reduced topical steroid therapy.